General Information of Drug Therapeutic Target (DTT) (ID: TTHI19T)

DTT Name Staphylococcus Beta-lactamase (Stap-coc blaZ)
Synonyms blaZ; Cephalosporinase
Gene Name Stap-coc blaZ
DTT Type
Successful target
[1]
BioChemical Class
Carbon-nitrogen hydrolase
UniProt ID
BLAC_STAAU
TTD ID
T38179
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.5.2.6
Sequence
MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
YASTSKAINSAILLEQVPYNKLNKKVHINKDDIVAYSPILEKYVGKDITLKALIEASMTY
SDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKT
LNKLIANGKLSKENKKFLLDLMLNNKSGDTLIKDGVPKDYKVADKSGQAITYASRNDVAF
VYPKGQSEPIVLVIFTNKDNKSDKPNDKLISETAKSVMKEF
Function This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [2]
Tazobactam DM3XNUI Appendicitis DB10 Approved [1]
------------------------------------------------------------------------------------
13 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CAZ AVI DMPG4OM Serious infection 1H0Z Phase 3 [3]
Enmetazobactam DMZKTYJ Urinary tract infection GC08 Phase 3 [4]
Vaborbactam DMDCFXJ Urinary tract infection GC08 Phase 3 [5]
CXL DM3JFZ2 Methicillin-resistant staphylococci infection 1A00-1A09 Phase 2 [6]
MK-7655 DMLMV0O Bacterial infection 1A00-1C4Z Phase 2 [7]
ETX0282 DMUBD0I Urinary tract infection GC08 Phase 1 [8]
ME-1071 DMEMQ5J Bacterial infection 1A00-1C4Z Phase 1 [9]
OP-0595 DMECVP9 Bacterial infection 1A00-1C4Z Phase 1 [10]
QPX7728 DMEXZQ2 Bacterial infection 1A00-1C4Z Phase 1 [11]
QPX7831 DMD2P1X Gram-negative bacterial infection 1B74-1G40 Phase 1 [12]
RASV-Sp DM4VTX6 Streptococcus infection 1B53 Phase 1 [13]
VNRX-5133 DMNZ6XH Bacterial infection 1A00-1C4Z Phase 1 [14]
XNW4107 DMT0747 Bacterial infection 1A00-1C4Z Phase 1 [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Clinical Trial Drug(s)
9 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2085-P DM0GMJ6 Otitis media AA80-AB0Z Discontinued in Phase 3 [16]
DA-7101 DMHSLVO Gram-positive bacterial infection 1B74-1G40 Discontinued in Phase 3 [17]
P1A DMWCAQD Toxicity N.A. Discontinued in Phase 2 [18]
BRL-42715 DMBC12X Bacterial infection 1A00-1C4Z Terminated [19]
CL-186659 DMYML2N Bacterial infection 1A00-1C4Z Terminated [16]
Ro-48-1220 DMXMP3D Bacterial infection 1A00-1C4Z Terminated [20]
Ro-48-5545 DM7AUF2 Bacterial infection 1A00-1C4Z Terminated [21]
Ro-48-8724 DM0RZEO Multidrug resistant infection MG51 Terminated [22]
SB-236049 DM5JDH1 Bacterial infection 1A00-1C4Z Terminated [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Discontinued Drug(s)
43 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(P-Iodophenylacetylamino)Methylphosphinic Acid DMB8NWI Discovery agent N.A. Investigative [24]
1-Aminopropane-1,2,3-tricarboxylic acid DMPYCK5 Discovery agent N.A. Investigative [25]
2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB Discovery agent N.A. Investigative [24]
2-(Sulfanylmethyl)phenylphosphonic acid DM5CEG8 Discovery agent N.A. Investigative [26]
2-mercaptophenylphosphonic acid DM8HSBT Discovery agent N.A. Investigative [26]
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [24]
2-phenyl-1H-imidazole-4-carboxylic acid DMZI7O1 Discovery agent N.A. Investigative [27]
3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid DMV4XGT Discovery agent N.A. Investigative [25]
3-ethoxycarbonylpyroglutamate DM4YL5Q Discovery agent N.A. Investigative [25]
3-Nitrophenylboronic Acid DMPMX8R Discovery agent N.A. Investigative [24]
4,4'-Biphenyldiboronic Acid DMFGQ02 Discovery agent N.A. Investigative [24]
4-(Carboxyvin-2-Yl)Phenylboronic Acid DMSG9LV Discovery agent N.A. Investigative [24]
4-Carboxyphenylboronic Acid DM8A2QO Discovery agent N.A. Investigative [24]
4-iodo-acetamido phenylboronic acid DMFSH2I Discovery agent N.A. Investigative [24]
4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid DMH6QZO Discovery agent N.A. Investigative [28]
4-[(METHYLSULFONYL)AMINO]BENZOIC ACID DMXKT6M Discovery agent N.A. Investigative [27]
5-Fluoro-2-sulfanyl-phenylphosphonic acid DMUCLAV Discovery agent N.A. Investigative [26]
5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid DMN9FPV Discovery agent N.A. Investigative [29]
5-methyl-benzo[b]thiophen-2-ylboronic acid DMLJVB7 Discovery agent N.A. Investigative [29]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [24]
Acylated Ceftazidime DMIZ5VO Discovery agent N.A. Investigative [24]
Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid DMWL172 Discovery agent N.A. Investigative [26]
Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid DM42M6I Discovery agent N.A. Investigative [26]
Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid DMRIWDV Discovery agent N.A. Investigative [26]
Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid DMP6GXU Discovery agent N.A. Investigative [26]
Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid DMP9V42 Discovery agent N.A. Investigative [26]
Alpha-Sulfanylbenzylphosphonic acid DMWB07I Discovery agent N.A. Investigative [26]
Alpha-Sulfanylpropylphosphonic acid DM19NAI Discovery agent N.A. Investigative [26]
Benzo[b]thiophen-2-ylboronic acid DMJQSLW Discovery agent N.A. Investigative [24]
Carbamic Acid DMJQ3LN Discovery agent N.A. Investigative [24]
Degraded Cephaloridine DMKRT20 Discovery agent N.A. Investigative [24]
Diisopropyl 1-mercaptopropylphosphonate DMNR439 Discovery agent N.A. Investigative [26]
Diisopropyl 2-(sulfanylmethyl)phenylphosphonate DMVFJAH Discovery agent N.A. Investigative [26]
Diisopropyl mercapto(phenyl)methylphosphonate DMHKE3M Discovery agent N.A. Investigative [26]
Hydrolyzed Cephalothin DMWH92F Discovery agent N.A. Investigative [24]
M-Aminophenylboronic Acid DM213MD Discovery agent N.A. Investigative [24]
N-2-Thiophen-2-Yl-Acetamide Boronic Acid DMLK0J8 Discovery agent N.A. Investigative [24]
PCNOTAXIME GROUP DMGS6YH Discovery agent N.A. Investigative [27]
Sucrose DMVWUCF Discovery agent N.A. Investigative [30]
Thiophene-2-ylboronic acid DML3OHW Discovery agent N.A. Investigative [29]
Tribenzyl 2-aminopropane-1,2,3-tricarboxylate DMYSX0K Discovery agent N.A. Investigative [25]
Triethyl 2-aminopropane-1,2,3-tricarboxylate DM5Q7K8 Discovery agent N.A. Investigative [25]
[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate DM86305 Discovery agent N.A. Investigative [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 43 Investigative Drug(s)

References

1 Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
2 A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
3 NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
4 Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
5 Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
6 Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
7 Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
8 Interactions of the Diazabicyclooctane Serine beta-Lactamase Inhibitor ETX1317 with Target Enzymes. ACS Infect Dis. 2021 Jan 8;7(1):114-122.
9 Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
10 OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
11 QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Front Microbiol. 2021 Jul 5;12:697180.
12 Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid beta-Lactamase Inhibitor QPX7728. J Med Chem. 2021 Dec 9;64(23):17523-17529.
13 WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
14 Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.
15 In vitro and in vivo activities of a novel beta-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. J Glob Antimicrob Resist. 2022 Dec;31:1-9.
16 US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
17 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
18 IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs. 2009 Aug;10(8):838-44.
19 In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1989 Sep;33(9):1580-7.
20 Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam beta-lactamase inhibitor. Clin Microbiol Infect. 1995 Feb;1(2):86-100.
21 Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother. 1997 Sep;40(3):335-43.
22 Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Diagn Microbiol Infect Dis. 1998 Oct;32(2):85-94.
23 Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6.
24 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
25 Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
26 Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
27 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
28 N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases. J Med Chem. 1988 Feb;31(2):370-4.
29 Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54.
30 Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39.